文献速递神经肿瘤

胶质瘤中的突变负荷、免疫检查点表达与错配修复:对免疫检查点免疫治疗的意义

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
PubMed 文献 · Neuro Oncol · 2017-01-01

本研究对2009至2016年提交分析的327例胶质瘤患者(含198例胶质母细胞瘤)进行生物标志物表型分析,发现高肿瘤突变负荷仅见于3.5%的胶质母细胞瘤患者(7/198),且与错配修复蛋白表达缺失及DNA错配修复突变相关;高及中等肿瘤突变负荷的胶质母细胞瘤并未富集CD8+ T细胞、PD-1+ T细胞或肿瘤表达的PD-L1,IDH1突变胶质瘤亦未富集高肿瘤突变负荷、PD-1+ T细胞或PD-L1表达。

要点

  • 高肿瘤突变负荷仅见于3.5%的胶质母细胞瘤患者(7/198)。
  • 高肿瘤突变负荷与MLH1、MSH2、MSH6、PMS2蛋白表达缺失及DNA错配修复突变相关。
  • 高及中等肿瘤突变负荷的胶质母细胞瘤未富集CD8+ T细胞、PD-1+ T细胞或PD-L1表达。

核心结论

  • 基于多种潜在的免疫检查点应答生物标志物,仅小部分胶质瘤患者可能从单药免疫检查点抑制中获益。

研究设计与样本

  • 研究对2009至2016年提交分析的327例胶质瘤患者(包括198例胶质母细胞瘤)进行了共享生物标志物表型分析。

主要发现

  • 高肿瘤突变负荷仅见于3.5%的胶质母细胞瘤患者(7/198),并与MLH1蛋白表达缺失(P = .0345)、MSH2蛋白表达缺失(P = .0099)、MSH6蛋白表达缺失(P = .0022)、PMS2蛋白表达缺失(P = .0345)及DNA错配修复突变的存在相关。
  • 高及中等肿瘤突变负荷的胶质母细胞瘤未富集CD8+ T细胞、PD-1+ T细胞或肿瘤表达的PD-L1。
  • IDH1突变胶质瘤未富集高肿瘤突变负荷、PD-1+ T细胞或PD-L1表达。

关键数值与推荐

  • 高肿瘤突变负荷在胶质母细胞瘤患者中占3.5%(7/198)。
  • 高肿瘤突变负荷与MLH1蛋白表达缺失相关(P = .0345)。
  • 高肿瘤突变负荷与MSH2蛋白表达缺失相关(P = .0099)。
  • 高肿瘤突变负荷与MSH6蛋白表达缺失相关(P = .0022)。
  • 高肿瘤突变负荷与PMS2蛋白表达缺失相关(P = .0345)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite a multiplicity of clinical trials testing immune checkpoint inhibitors, the frequency of expression of potential predictive biomarkers is unknown in glioma. METHODS: In this study, we profiled the frequency of shared biomarker phenotypes. To clarify the relationships among tumor mutational load (TML), mismatch repair (MMR), and immune checkpoint expression, we profiled patients with glioma (n = 327), including glioblastoma (GBM) (n = 198), whose samples had been submitted for analysis from 2009 to 2016. The calculation algorithm for TML included nonsynonymous mutation counts per tumor, with germline mutations filtered out. Immunohistochemical analysis and next-generation sequencing were used to determine tumor-infiltrating lymphocyte expression positive for programmed cell death protein 1 (PD-1), PD ligand 1 (PD-L1) expression on tumor cells, MMR (MLH1, MSH2, MSH6, and PMS2) protein expression and mutations, and DNA polymerase epsilon (POLE) mutations. RESULTS: High TML was only found in 3.5% of GBM patients (7 of 198) and was associated with the absence of protein expression of mutL homolog 1 (MLH1) (P = .0345), mutS homolog 2 (MSH2) (P = .0099), MSH6 (P = .0022), and postmeiotic segregation increased 2 (PMS2) (P = .0345) and the presence of DNA MMR mutations. High and moderate TML GBMs did not have an enriched influx of CD8+ T cells, PD-1+ T cells, or tumor-expressed PD-L1. IDH1 mutant gliomas were not enriched for high TML, PD-1+ T cells, or PD-L1 expression. CONCLUSIONS: To clarify the relationships among TML, MMR, and immune checkpoint expression, we profiled the frequency of shared biomarker phenotypes. On the basis of a variety of potential biomarkers of response to immune checkpoints, only small subsets of glioma patients are likely to benefit from monotherapy immune checkpoint inhibition.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Hodges TR, Ott M, Xiu J, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017. PMID: 28371827. doi:10.1093/neuonc/nox026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。